Showing 3581-3590 of 5621 results for "".
- SIFI Receives European Commission Approval for Akantiorhttps://modernod.com/news/avanzanite-bioscience-secures-european-commission-approval-for-akantior-first-treatment-for-acanthamoeba-keratitis/2482417/SIFI announced the European Commission has approved Akantior (polihexanide) for the treatment of acanthamoeba keratitis (AK) in adults and children from 12 years of age. Akantior is the first and only approved therapy for people suffering from AK in Europe. AK is an ultr
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and
- Injectsense Completes First Successful Human Implant of Ultraminiature Intraocular Pressure Sensorhttps://modernod.com/news/injectsense-completes-first-successful-human-implant-of-ultraminiature-intraocular-pressure-sensor/2482413/Injectsense has announced the completion of the first human implant and subsequent wireless IOP measurements using its ultraminiature implantable sensor, which has received FDA breakthrough designation. The IOP-Connect system study is being conducted under the leadership
- Ocugen Receives Health Canada Approval to Initiate Phase 3 Clinical Trial for Retinitis Pigmentosahttps://modernod.com/news/ocugen-receives-health-canada-approval-to-initiate-phase-3-clinical-trial-for-retinitis-pigmentosa/2482410/Ocugen announced that Health Canada has provided a “No Objection Letter” to initiate the phase 3 Limelight clinical trial for OCU400 in Canada. OCU400 is a modifier gene therapy product candidate designed for the treatment of retinitis pigmentosa (RP). "Expand
- Inaugural Eyecelerator Innovation Award Presented to Regeneron Executiveshttps://modernod.com/news/inaugural-eyecelerator-innovation-award-presented-to-regeneron-executives/2482404/Leonard Schleifer, MD, PhD, and George Yancopoulos, MD, PhD, of Regeneron Pharmaceuticals were awarded the first Eyecelerator Innovation Award. "This year's Eyecelerator Innovation Award honors the remarkable physician-led, science-dr
- Ocuvex Therapeutics Acquires Visiox Pharmaceuticalshttps://modernod.com/news/visiox-pharmaceuticals-merges-with-ocuvex-therapeutics/2482402/Early-stage ophthalmic biotech company Ocuvex Therapeutics announced an agreement to acquire Visiox Pharmaceuticals. Terms of the deal were not disclosed. Visiox's lead asset is Omlonti (omidenepag isopropyl ophthalmic solution 0.002%), an EP2 rece
- Orbis Launches AI-Led Diabetic Retinopathy Screening Project in Vietnamhttps://modernod.com/news/orbis-launches-ai-led-diabetic-retinopathy-screening-project-in-vietnam/2482401/Orbis has launched an AI-led diabetic retinopathy (DR) project in Vietnam, aiming to screen 72,000 people with diabetes over the next 3 years. The initiative focuses on providing AI-driven screenings, specialized training for screening teams, and enhancing community awareness of diabeti
- Lenz Therapeutics Submits NDA for LNZ100 Eye Drop for Presbyopiahttps://modernod.com/news/lenz-therapeutics-submits-new-drug-application-for-lnz100-eye-drop-for-presbyopia-treatment/2482397/Lenz Therapeutics has submitted a new drug application (NDA) to the FDA for LNZ100, an investigational presbyopia eye drop. This aceclidine-based ophthalmic solution is designed to improve near vision in people with presbyopia. The NDA submission follows the successful completion o
- Sandoz Receives FDA Approval for Eylea Biosimilar Enzeevuhttps://modernod.com/news/sandoz-receives-fda-approval-for-eylea-biosimilar-enzeevu/2482396/The FDA has approved Sandoz's Enzeevu (aflibercept-abzv), an Eylea biosimilar, for the treatment of wet age-related macular degeneration (AMD). The approval includes both a 2 mg vial kit and a pre-filled syringe for intravitreal injection. The FDA provisionally
- Lensar's ALLY Adaptive Cataract Treatment System Approved in Europehttps://modernod.com/news/lensars-ally-adaptive-cataract-treatment-system-approved-in-europe/2482390/Lensar announced that the ALLY Adaptive Cataract Treatment System is now commercially available in Europe after receiving certification under the European Union’s Medical Device Regulation (MDR). Lensar is commercializing ALLY through its di